Arthrosi Therapeutics has closed a $153 million Series E funding round. This late-stage biotechnology company is focused on developing a next-generation URAT1 inhibitor, which has the potential to be a best-in-class treatment for patients suffering from gout and tophaceous gout. Prime Eight Capital Limited led the funding, with participation from several notable investors, including CR Biotech, HighLight Capital, HM Venture Partners, and ReliantTech Limited, as well as existing shareholders.
The funds raised are earmarked for finalizing the clinical development of Arthrosi’s lead program, pozdeutinurad (AR882). This program is currently undergoing Phase 3 trials named REDUCE 1 and REDUCE 2. The trials are designed to evaluate the ability of pozdeutinurad to effectively reduce serum urate (sUA) levels in patients diagnosed with gout and tophaceous gout. These studies are substantial in scope, lasting twelve months and employing a randomized, double-blind, placebo-controlled design to ensure robust and reliable results.
A key focus of the Phase 3 trials is not only on lowering sUA levels but also on assessing how well pozdeutinurad can mitigate the occurrence of gout flares and dissolve tophi, which are painful deposits of urate crystals.
The trials have now fully enrolled participants, marking a crucial step toward gathering valuable data. With the expectation to report pivotal data by the second quarter of 2026, Arthrosi is on track to progress its innovative treatment closer to market introduction.
This funding represents a significant leap forward in the company’s mission to improve the lives of individuals affected by gout.
KEY QUOTES:
“We are delighted to have the continued support of an experienced and deeply committed group of investors. Arthrosi continues to make rapid progress on our mission to transform the treatment landscape for gout and tophaceous gout, an area with pressing unmet need. The commitment from both new and existing investors provides further validation for pozdeutinurad and the robust clinical data package we have generated to date. With their support, we look forward to advancing our pivotal Phase 3 program as we work to deliver pozdeutinurad’s potentially transformative benefits to patients as soon as possible.”
Litain Yeh, Ph.D., Founder and CEO of Arthrosi Therapeutics
“We’re excited to partner with Arthrosi as they advance pozdeutinurad through late-stage development. The company’s strong management team with a focus on execution gives us confidence in Arthrosi’s ability to deliver a potentially best-in-class treatment for gout. We share their vision to make pozdeutinurad accessible to patients globally and are proud to support a team with the expertise, discipline, and urgency to make that vision a reality.”
Prime Eight Capital
